Prognostic value of nuclear morphometry in myxoid liposarcoma
Myxoid liposarcoma (MLS) accounts for 20%‐30% of liposarcoma and the round cell component (RCC) is believed to be a specific poor prognostic factor. However, the RCC assessment criteria are vaguely defined and, therefore, are inconsistently employed by pathologists. In this study, we modified and ap...
Saved in:
Published in: | Cancer science Vol. 114; no. 5; pp. 2178 - 2188 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
England
John Wiley & Sons, Inc
01-05-2023
John Wiley and Sons Inc |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Myxoid liposarcoma (MLS) accounts for 20%‐30% of liposarcoma and the round cell component (RCC) is believed to be a specific poor prognostic factor. However, the RCC assessment criteria are vaguely defined and, therefore, are inconsistently employed by pathologists. In this study, we modified and applied two established grading systems to evaluate nuclear atypia (namely, the World Health Organization/International Society of Urological Pathology and the Fuhrman grading in renal cell carcinoma) in 64 MLS cases. Detailed software‐based assessments of the morphology and the cellularity were performed. DNA mutation analysis, comprehensive mRNA expression analysis, and immunohistochemistry were also performed. Our findings revealed that the high–nuclear‐grade group according to the modified Fuhrman grading system exhibited a significantly poor disease‐free survival (hazard ratio: 4.43; 95% confidence interval: 0.9‐22.6; p = 0.047). On the other hand, the cellularity was significantly higher in the modified Fuhrman high‐grade group (p = 0.010 at the percentage of the hypercellular area; p = 0.003 at the maximum cell density) but did not qualify per se as a poor prognostic factor in the survival analyses. Furthermore, the modified Fuhrman high‐grade group significantly expressed the cell cycle–related genes (such as FOXM1, PLK1, and CDK1). In conclusion, our analyses suggest that an evaluation focusing on nuclear morphology (rather than on cellular density) can be more reliable in predicting the MLS prognosis.
The evaluation focusing on nuclear morphology (rather than on cellular density) can be more reliable in predicting the myxoid liposarcoma (MLS) prognosis. Modified Fuhrman grading is useful for the morphology evaluation. The high–nuclear‐grade group significantly expressed the cell cycle–related genes (such as FOXM1, PLK1, and CDK1). |
---|---|
AbstractList | Myxoid liposarcoma (MLS) accounts for 20%-30% of liposarcoma and the round cell component (RCC) is believed to be a specific poor prognostic factor. However, the RCC assessment criteria are vaguely defined and, therefore, are inconsistently employed by pathologists. In this study, we modified and applied two established grading systems to evaluate nuclear atypia (namely, the World Health Organization/International Society of Urological Pathology and the Fuhrman grading in renal cell carcinoma) in 64 MLS cases. Detailed software-based assessments of the morphology and the cellularity were performed. DNA mutation analysis, comprehensive mRNA expression analysis, and immunohistochemistry were also performed. Our findings revealed that the high–nuclear-grade group according to the modified Fuhrman grading system exhibited a significantly poor disease-free survival (hazard ratio: 4.43; 95% confidence interval: 0.9-22.6; p = 0.047). On the other hand, the cellularity was significantly higher in the modified Fuhrman high-grade group (p = 0.010 at the percentage of the hypercellular area; p = 0.003 at the maximum cell density) but did not qualify per se as a poor prognostic factor in the survival analyses. Furthermore, the modified Fuhrman high-grade group significantly expressed the cell cycle–related genes (such as FOXM1, PLK1, and CDK1). In conclusion, our analyses suggest that an evaluation focusing on nuclear morphology (rather than on cellular density) can be more reliable in predicting the MLS prognosis. Myxoid liposarcoma (MLS) accounts for 20%‐30% of liposarcoma and the round cell component (RCC) is believed to be a specific poor prognostic factor. However, the RCC assessment criteria are vaguely defined and, therefore, are inconsistently employed by pathologists. In this study, we modified and applied two established grading systems to evaluate nuclear atypia (namely, the World Health Organization/International Society of Urological Pathology and the Fuhrman grading in renal cell carcinoma) in 64 MLS cases. Detailed software‐based assessments of the morphology and the cellularity were performed. DNA mutation analysis, comprehensive mRNA expression analysis, and immunohistochemistry were also performed. Our findings revealed that the high–nuclear‐grade group according to the modified Fuhrman grading system exhibited a significantly poor disease‐free survival (hazard ratio: 4.43; 95% confidence interval: 0.9‐22.6; p = 0.047). On the other hand, the cellularity was significantly higher in the modified Fuhrman high‐grade group (p = 0.010 at the percentage of the hypercellular area; p = 0.003 at the maximum cell density) but did not qualify per se as a poor prognostic factor in the survival analyses. Furthermore, the modified Fuhrman high‐grade group significantly expressed the cell cycle–related genes (such as FOXM1, PLK1, and CDK1). In conclusion, our analyses suggest that an evaluation focusing on nuclear morphology (rather than on cellular density) can be more reliable in predicting the MLS prognosis. The evaluation focusing on nuclear morphology (rather than on cellular density) can be more reliable in predicting the myxoid liposarcoma (MLS) prognosis. Modified Fuhrman grading is useful for the morphology evaluation. The high–nuclear‐grade group significantly expressed the cell cycle–related genes (such as FOXM1, PLK1, and CDK1). Myxoid liposarcoma (MLS) accounts for 20%‐30% of liposarcoma and the round cell component (RCC) is believed to be a specific poor prognostic factor. However, the RCC assessment criteria are vaguely defined and, therefore, are inconsistently employed by pathologists. In this study, we modified and applied two established grading systems to evaluate nuclear atypia (namely, the World Health Organization/International Society of Urological Pathology and the Fuhrman grading in renal cell carcinoma) in 64 MLS cases. Detailed software‐based assessments of the morphology and the cellularity were performed. DNA mutation analysis, comprehensive mRNA expression analysis, and immunohistochemistry were also performed. Our findings revealed that the high–nuclear‐grade group according to the modified Fuhrman grading system exhibited a significantly poor disease‐free survival (hazard ratio: 4.43; 95% confidence interval: 0.9‐22.6; p = 0.047). On the other hand, the cellularity was significantly higher in the modified Fuhrman high‐grade group ( p = 0.010 at the percentage of the hypercellular area; p = 0.003 at the maximum cell density) but did not qualify per se as a poor prognostic factor in the survival analyses. Furthermore, the modified Fuhrman high‐grade group significantly expressed the cell cycle–related genes (such as FOXM1 , PLK1 , and CDK1 ). In conclusion, our analyses suggest that an evaluation focusing on nuclear morphology (rather than on cellular density) can be more reliable in predicting the MLS prognosis. Myxoid liposarcoma (MLS) accounts for 20%-30% of liposarcoma and the round cell component (RCC) is believed to be a specific poor prognostic factor. However, the RCC assessment criteria are vaguely defined and, therefore, are inconsistently employed by pathologists. In this study, we modified and applied two established grading systems to evaluate nuclear atypia (namely, the World Health Organization/International Society of Urological Pathology and the Fuhrman grading in renal cell carcinoma) in 64 MLS cases. Detailed software-based assessments of the morphology and the cellularity were performed. DNA mutation analysis, comprehensive mRNA expression analysis, and immunohistochemistry were also performed. Our findings revealed that the high-nuclear-grade group according to the modified Fuhrman grading system exhibited a significantly poor disease-free survival (hazard ratio: 4.43; 95% confidence interval: 0.9-22.6; p = 0.047). On the other hand, the cellularity was significantly higher in the modified Fuhrman high-grade group (p = 0.010 at the percentage of the hypercellular area; p = 0.003 at the maximum cell density) but did not qualify per se as a poor prognostic factor in the survival analyses. Furthermore, the modified Fuhrman high-grade group significantly expressed the cell cycle-related genes (such as FOXM1, PLK1, and CDK1). In conclusion, our analyses suggest that an evaluation focusing on nuclear morphology (rather than on cellular density) can be more reliable in predicting the MLS prognosis. Myxoid liposarcoma (MLS) accounts for 20%‐30% of liposarcoma and the round cell component (RCC) is believed to be a specific poor prognostic factor. However, the RCC assessment criteria are vaguely defined and, therefore, are inconsistently employed by pathologists. In this study, we modified and applied two established grading systems to evaluate nuclear atypia (namely, the World Health Organization/International Society of Urological Pathology and the Fuhrman grading in renal cell carcinoma) in 64 MLS cases. Detailed software‐based assessments of the morphology and the cellularity were performed. DNA mutation analysis, comprehensive mRNA expression analysis, and immunohistochemistry were also performed. Our findings revealed that the high–nuclear‐grade group according to the modified Fuhrman grading system exhibited a significantly poor disease‐free survival (hazard ratio: 4.43; 95% confidence interval: 0.9‐22.6; p = 0.047). On the other hand, the cellularity was significantly higher in the modified Fuhrman high‐grade group ( p = 0.010 at the percentage of the hypercellular area; p = 0.003 at the maximum cell density) but did not qualify per se as a poor prognostic factor in the survival analyses. Furthermore, the modified Fuhrman high‐grade group significantly expressed the cell cycle–related genes (such as FOXM1 , PLK1 , and CDK1 ). In conclusion, our analyses suggest that an evaluation focusing on nuclear morphology (rather than on cellular density) can be more reliable in predicting the MLS prognosis. The evaluation focusing on nuclear morphology (rather than on cellular density) can be more reliable in predicting the myxoid liposarcoma (MLS) prognosis. Modified Fuhrman grading is useful for the morphology evaluation. The high–nuclear‐grade group significantly expressed the cell cycle–related genes (such as FOXM1, PLK1, and CDK1 ). |
Author | Nakashima, Yasuharu Oda, Yoshinao Iwasaki, Takeshi Yamamoto, Hidetaka Yamamoto, Takeo Ishihara, Shin Kawaguchi, Kengo Kohashi, Kenichi Toda, Yu |
AuthorAffiliation | 1 Department of Anatomic Pathology, Graduate School of Medical Sciences Kyushu University Fukuoka Japan 2 Department of Orthopaedic Surgery, Graduate School of Medical Sciences Kyushu University Fukuoka Japan |
AuthorAffiliation_xml | – name: 2 Department of Orthopaedic Surgery, Graduate School of Medical Sciences Kyushu University Fukuoka Japan – name: 1 Department of Anatomic Pathology, Graduate School of Medical Sciences Kyushu University Fukuoka Japan |
Author_xml | – sequence: 1 givenname: Kengo surname: Kawaguchi fullname: Kawaguchi, Kengo organization: Kyushu University – sequence: 2 givenname: Kenichi surname: Kohashi fullname: Kohashi, Kenichi organization: Kyushu University – sequence: 3 givenname: Takeshi surname: Iwasaki fullname: Iwasaki, Takeshi organization: Kyushu University – sequence: 4 givenname: Takeo surname: Yamamoto fullname: Yamamoto, Takeo organization: Kyushu University – sequence: 5 givenname: Shin surname: Ishihara fullname: Ishihara, Shin organization: Kyushu University – sequence: 6 givenname: Yu surname: Toda fullname: Toda, Yu organization: Kyushu University – sequence: 7 givenname: Hidetaka surname: Yamamoto fullname: Yamamoto, Hidetaka organization: Kyushu University – sequence: 8 givenname: Yasuharu surname: Nakashima fullname: Nakashima, Yasuharu organization: Kyushu University – sequence: 9 givenname: Yoshinao orcidid: 0000-0001-9636-1182 surname: Oda fullname: Oda, Yoshinao email: oda.yoshinao.389@m.kyushu‐u.ac.jp organization: Kyushu University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36661410$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kctKAzEUhoMoXqoLX0AG3Oii9eQymclCpBRvICio65BmMjUyk9SkU-3bG1sVFczmhOTj4z_8O2jdeWcQ2scwwOmcaBUHOC-IWEPbmDLRLwD4-vJe9AVQsoV2YnwGoJwJtom2KOccMwzb6PQu-InzcWZ1NldNZzJfZ67TjVEha32YPvnWzMIisy5rF2_eVlljpz6qoH2rdtFGrZpo9j5nDz1enD-Mrvo3t5fXo-FNX-cfcbQmoEhVGcCFwuOaQskMVEJxRqkulFJQpZccGNC8qDgrxpxqTEohoKa0oj10tvJOu3FrKm3cLKhGToNtVVhIr6z8_ePsk5z4ucSAc1aKMhmOPg3Bv3QmzmRrozZNo5zxXZSk4CVhJC9JQg__oM--Cy7tJ0mZkjOBeZ6o4xWlg48xmPo7DQb50YpMrchlK4k9-Bn_m_yqIQEnK-DVNmbxv0mOhvcr5TuyvJgj |
CitedBy_id | crossref_primary_10_1007_s00428_023_03631_5 crossref_primary_10_3390_cancers16112026 crossref_primary_10_1136_jcp_2023_208963 crossref_primary_10_1007_s00428_024_03796_7 crossref_primary_10_1136_jcp_2023_208814 |
Cites_doi | 10.1038/onc.2016.157 10.1002/cncr.31176 10.1038/75556 10.1097/00000478-198210000-00007 10.1038/s41379-021-00972-x 10.1039/C5MB00663E 10.1038/ncb1217 10.1038/s41374-018-0057-0 10.15252/emmm.201809889 10.1245/s10434-006-9043-7 10.3390/ijms19020608 10.1038/modpathol.2011.148 10.1038/modpathol.2011.219 10.18632/oncotarget.10373 10.1007/s13277-015-4351-9 10.1186/1747-1028-5-11 10.1093/nar/gkw937 10.1155/2011/538085 10.1007/978-1-4899-8032-8_25 10.1148/radiol.2282011860 10.1111/j.0006-341X.2000.00337.x 10.1002/cncr.27847 10.1038/nprot.2012.004 10.1038/bjc.2012.424 10.1093/bioinformatics/btp616 10.1038/nrc3219 10.1186/1747-1028-3-4 10.1002/(SICI)1097-0142(19960415)77:8<1450::AID-CNCR5>3.0.CO;2-G 10.1038/s41598-019-56247-8 10.1186/1756-9966-33-33 10.1111/cas.15256 10.1038/s41598-017-17204-5 10.1186/s12964-018-0266-6 10.1159/000508780 10.1002/cncr.22720 10.1007/s00432-020-03438-w 10.3390/uro1010002 10.1515/BC.2007.159 10.1038/s41467-022-30847-x 10.1002/path.1848 10.1002/cjp2.16 10.1245/s10434-011-2127-z 10.11613/BM.2012.031 |
ContentType | Journal Article |
Copyright | 2023 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. 2023. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2023 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. – notice: 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. – notice: 2023. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P WIN CGR CUY CVF ECM EIF NPM AAYXX CITATION 8FE 8FH ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ HCIFZ LK8 M7P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1111/cas.15729 |
DatabaseName | Wiley Open Access Wiley Free Archive Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Databases ProQuest Natural Science Collection ProQuest One Community College ProQuest Central ProQuest Central Student SciTech Premium Collection Biological Sciences Biological Science Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Student ProQuest Biological Science Collection ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection Biological Science Database ProQuest SciTech Collection ProQuest Central China ProQuest Central ProQuest One Academic UKI Edition Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest One Academic MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Kawaguchi et al |
EISSN | 1349-7006 |
EndPage | 2188 |
ExternalDocumentID | 10_1111_cas_15729 36661410 CAS15729 |
Genre | researchArticle Journal Article |
GrantInformation_xml | – fundername: Japan Society for the Promotion of Science funderid: 19H03444; 21K06887; 21K20805 – fundername: Japan Society for the Promotion of Science grantid: 21K06887 – fundername: Japan Society for the Promotion of Science grantid: 21K20805 – fundername: Japan Society for the Promotion of Science grantid: 19H03444 – fundername: ; grantid: 19H03444; 21K06887; 21K20805 |
GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OC 24P 29B 2WC 31~ 36B 3O- 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52W 52X 53G 5GY 5HH 5LA 5VS 66C 7.U 702 7PT 8-0 8-1 8-3 8-4 8-5 8FE 8FH 8UM 930 A01 A03 AAHHS AAZKR ABCQN ABEML ACCFJ ACSCC ACXQS ADBBV ADKYN ADZMN ADZOD AEEZP AENEX AEQDE AFBPY AFEBI AFFNX AFKRA AFPKN AFZJQ AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU BAWUL BBNVY BCNDV BENPR BFHJK BHPHI BY8 CAG CCPQU COF CS3 D-6 D-7 D-E D-F DIK DR2 DU5 E3Z EBS EJD EMB EMOBN EX3 F00 F01 F04 F5P FIJ GODZA GROUPED_DOAJ HCIFZ HF~ HOLLA HYE HZI HZ~ IAO IHR IPNFZ IX1 J0M K.9 K48 KQ8 LC2 LC3 LH4 LK8 LP6 LP7 LW6 M7P MK4 N04 N05 N9A O9- OIG OK1 OVD P2P P2X P2Z P4B P4D PIMPY PROAC Q11 ROL RPM RX1 SJN SUPJJ SV3 TEORI UB1 W8V WIN WOW WQJ WRC WXI X7M XG1 ZXP ~IA ~WT CGR CUY CVF ECM EIF ITC NPM AAYXX CITATION ABUWG AZQEC DWQXO GNUQQ PQEST PQQKQ PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c5349-cc20a2dde017a1bf3084e0d9a6433c7aaa0d84e5040357d647b63c128990f33d3 |
IEDL.DBID | RPM |
ISSN | 1347-9032 |
IngestDate | Tue Sep 17 21:30:56 EDT 2024 Fri Oct 25 05:57:33 EDT 2024 Thu Oct 10 22:42:14 EDT 2024 Fri Nov 22 02:47:33 EST 2024 Sat Sep 28 08:13:22 EDT 2024 Sat Aug 24 00:51:22 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | cell cycle-related gene morphometry myxoid liposarcoma round cell component nuclear atypia |
Language | English |
License | Attribution-NonCommercial 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5349-cc20a2dde017a1bf3084e0d9a6433c7aaa0d84e5040357d647b63c128990f33d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0001-9636-1182 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154898/ |
PMID | 36661410 |
PQID | 2808449165 |
PQPubID | 4378882 |
PageCount | 11 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10154898 proquest_miscellaneous_2768242582 proquest_journals_2808449165 crossref_primary_10_1111_cas_15729 pubmed_primary_36661410 wiley_primary_10_1111_cas_15729_CAS15729 |
PublicationCentury | 2000 |
PublicationDate | May 2023 |
PublicationDateYYYYMMDD | 2023-05-01 |
PublicationDate_xml | – month: 05 year: 2023 text: May 2023 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Tokyo – name: Hoboken |
PublicationTitle | Cancer science |
PublicationTitleAlternate | Cancer Sci |
PublicationYear | 2023 |
Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc |
Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc |
References | 2015; 1 2017; 7 2019; 9 2007; 388 2020; 64 2000; 25 2019; 11 2021; 147 2018; 124 2017; 45 2012; 19 2008; 3 2021; 1 2012; 12 2007; 109 2016; 37 2012; 107 2016; 35 2007; 14 2022; 113 2016; 12 2014; 773 1996; 77 2011; 2011 2021; 35 2018; 19 2016; 7 2003; 228 2010; 26 2013; 119 2022 2000; 56 2020 1982; 6 2019 2005; 207 2022; 13 2005; 7 2012; 25 2012; 7 2018; 98 2010; 5 2012; 22 2018; 16 2014; 33 e_1_2_10_23_1 e_1_2_10_46_1 e_1_2_10_24_1 e_1_2_10_45_1 e_1_2_10_21_1 e_1_2_10_44_1 e_1_2_10_22_1 e_1_2_10_43_1 e_1_2_10_42_1 e_1_2_10_20_1 e_1_2_10_41_1 e_1_2_10_40_1 Goldblum J (e_1_2_10_7_1) 2019 e_1_2_10_2_1 e_1_2_10_4_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_16_1 e_1_2_10_39_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_38_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_37_1 e_1_2_10_15_1 e_1_2_10_36_1 e_1_2_10_12_1 e_1_2_10_35_1 e_1_2_10_9_1 e_1_2_10_13_1 e_1_2_10_34_1 e_1_2_10_10_1 e_1_2_10_33_1 e_1_2_10_11_1 e_1_2_10_32_1 e_1_2_10_31_1 e_1_2_10_30_1 WHO Classification of Tumours Editorial Board (e_1_2_10_6_1) 2020 WHO Classification of Tumours Editorial Board (e_1_2_10_18_1) 2022 e_1_2_10_29_1 e_1_2_10_27_1 e_1_2_10_28_1 e_1_2_10_25_1 e_1_2_10_26_1 e_1_2_10_47_1 |
References_xml | – volume: 25 start-page: 212 year: 2012 end-page: 221 article-title: Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma publication-title: Mod Pathol – volume: 35 start-page: 6177 year: 2016 end-page: 6188 article-title: miR‐135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma publication-title: Oncogene – volume: 6 start-page: 655 year: 1982 end-page: 663 article-title: Prognostic significance of morphologic parameters in renal cell carcinoma publication-title: Am J Surg Pathol – volume: 25 start-page: 25 year: 2000 end-page: 29 article-title: Gene ontology: tool for the unification of biology publication-title: Nat Genet – volume: 124 start-page: 1179 year: 2018 end-page: 1187 article-title: Presentation and outcome of frequent and rare sarcoma histologic subtypes: a study of 10,262 patients with localized visceral/soft tissue sarcoma managed in reference centers publication-title: Cancer – volume: 16 start-page: 57 year: 2018 article-title: Regulation of the master regulator FOXM1 in cancer publication-title: Cell Commun Signal – volume: 12 start-page: 477 year: 2016 end-page: 479 article-title: ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization publication-title: Mol Biosyst – volume: 7 start-page: 126 year: 2005 end-page: 136 article-title: FoxM1 is required for execution of the mitotic programme and chromosome stability publication-title: Nat Cell Biol – volume: 56 start-page: 337 issue: 2 year: 2000 end-page: 344 article-title: Time‐dependent ROC curves for censored survival data and a diagnostic marker publication-title: Biometrics – volume: 7 start-page: 670 year: 2012 end-page: 685 article-title: Topological analysis and interactive visualization of biological networks and protein structures publication-title: Nat Protoc – volume: 19 start-page: 608 year: 2018 article-title: Presence of TERT promoter mutations is a secondary event and associates with elongated telomere length in myxoid liposarcomas publication-title: Int J Mol Sci – volume: 19 start-page: 1081 year: 2012 end-page: 1088 article-title: Myxoid/round cell liposarcoma (MRCLS) revisited: an analysis of 418 primarily managed cases publication-title: Ann Surg Oncol – volume: 33 start-page: 33 year: 2014 article-title: TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities publication-title: J Exp Clin Cancer Res – volume: 109 start-page: 2522 year: 2007 end-page: 2531 article-title: Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution publication-title: Cancer – volume: 12 start-page: 196 year: 2012 end-page: 209 article-title: The nuclear envelope environment and its cancer connections publication-title: Nat Rev Cancer – volume: 37 start-page: 5213 year: 2016 end-page: 5223 article-title: FOXM1 expression in rhabdomyosarcoma: a novel prognostic factor and therapeutic target publication-title: Tumour Biol – volume: 45 start-page: D362 year: 2017 end-page: D368 article-title: The STRING database in 2017: quality‐controlled protein‐protein association networks, made broadly accessible publication-title: Nucleic Acids Res – volume: 3 start-page: 4 year: 2008 article-title: Self‐regulated mechanism of Plk1 localization to kinetochores: lessons from the Plk1‐PBIP1 interaction publication-title: Cell Div – volume: 22 start-page: 276 year: 2012 end-page: 282 article-title: Interrater reliability: the kappa statistic publication-title: Biochem Med (Zagreb) – volume: 13 start-page: 3107 year: 2022 article-title: Establishment of mouse model of inherited PIGO deficiency and therapeutic potential of AAV‐based gene therapy publication-title: Nat Commun – volume: 147 start-page: 1499 year: 2021 end-page: 1518 article-title: The forkhead box M1 (FOXM1) expression and antitumor effect of FOXM1 inhibition in malignant rhabdoid tumor publication-title: J Cancer Res Clin Oncol – volume: 64 start-page: 511 year: 2020 end-page: 519 article-title: Nuclear morphology and the biology of cancer cells publication-title: Acta Cytol – volume: 388 start-page: 1257 year: 2007 end-page: 1274 article-title: FOXM1, a typical proliferation‐associated transcription factor publication-title: Biol Chem – volume: 1 start-page: 2 year: 2021 end-page: 13 article-title: Comparing World Health Organization/International Society of Urological Pathology Grading and Fuhrman Grading with the prognostic value of nuclear area in patients with renal cell carcinoma publication-title: Uro – volume: 2011 year: 2011 article-title: Prognostic factors and metastatic patterns in primary myxoid/round‐cell liposarcoma publication-title: Sarcoma – volume: 77 start-page: 1450 year: 1996 end-page: 1458 article-title: The clinicopathologic spectrum of myxoid and round cell liposarcoma: a study of 95 cases publication-title: Cancer – volume: 7 start-page: 49481 year: 2016 end-page: 49497 article-title: Accumulation of cytoplasmic Cdk1 is associated with cancer growth and survival rate in epithelial ovarian cancer publication-title: Oncotarget – volume: 773 start-page: 537 year: 2014 end-page: 569 article-title: Mechanisms of nuclear size regulation in model systems and cancer publication-title: Adv Exp Med Biol – volume: 107 start-page: 1766 year: 2012 end-page: 1775 article-title: The FOXM1‐PLK1 axis is commonly upregulated in oesophageal adenocarcinoma publication-title: Br J Cancer – volume: 35 start-page: 640 year: 2021 end-page: 648 article-title: Histological and immunohistochemical features and genetic alterations in the malignant progression of giant cell tumor of bone: a possible association with TP53 mutation and loss of H3K27 trimethylation publication-title: Mod Pathol – volume: 1 start-page: 144 year: 2015 end-page: 159 article-title: Cancer‐testis antigens PRAME and NY‐ESO‐1 correlate with tumour grade and poor prognosis in myxoid liposarcoma publication-title: J Pathol Clin Res – volume: 9 start-page: 19704 year: 2019 article-title: Prevalence of the hippo effectors YAP1/TAZ in tumors of soft tissue and bone publication-title: Sci Rep – volume: 119 start-page: 1868 year: 2013 end-page: 1877 article-title: Localized and metastatic myxoid/round cell liposarcoma: clinical and molecular observations publication-title: Cancer – volume: 25 start-page: 869 year: 2012 end-page: 876 article-title: Semi‐quantitative immunohistochemical assay versus oncotype DX® qRT‐PCR assay for estrogen and progesterone receptors: an independent quality assurance study publication-title: Mod Pathol – year: 2022 – volume: 228 start-page: 303 year: 2003 end-page: 308 article-title: Measurement of observer agreement publication-title: Radiology – volume: 26 start-page: 139 year: 2010 end-page: 140 article-title: edgeR: a Bioconductor package for differential expression analysis of digital gene expression data publication-title: Bioinformatics – year: 2020 – volume: 113 start-page: 1078 year: 2022 end-page: 1089 article-title: High prevalence of TERT aberrations in myxoid liposarcoma: TERT reactivation may play a crucial role in tumorigenesis publication-title: Cancer Sci – volume: 98 start-page: 844 year: 2018 end-page: 855 article-title: Principles and approaches for reproducible scoring of tissue stains in research publication-title: Lab Invest – volume: 11 year: 2019 article-title: Requirement for YAP1 signaling in myxoid liposarcoma publication-title: EMBO mol Med – volume: 5 start-page: 11 year: 2010 article-title: An overview of Cdk1‐controlled targets and processes publication-title: Cell Div – volume: 7 start-page: 16878 year: 2017 article-title: QuPath: open source software for digital pathology image analysis publication-title: Sci Rep – volume: 14 start-page: 222 year: 2007 end-page: 229 article-title: Clinicopathologic prognostic factors in myxoid liposarcoma: a retrospective study of 49 patients with long‐term follow‐up publication-title: Ann Surg Oncol – year: 2019 – volume: 207 start-page: 410 year: 2005 end-page: 421 article-title: Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis publication-title: J Pathol – ident: e_1_2_10_13_1 doi: 10.1038/onc.2016.157 – ident: e_1_2_10_8_1 doi: 10.1002/cncr.31176 – ident: e_1_2_10_27_1 doi: 10.1038/75556 – ident: e_1_2_10_19_1 doi: 10.1097/00000478-198210000-00007 – ident: e_1_2_10_24_1 doi: 10.1038/s41379-021-00972-x – ident: e_1_2_10_28_1 doi: 10.1039/C5MB00663E – ident: e_1_2_10_47_1 doi: 10.1038/ncb1217 – ident: e_1_2_10_31_1 doi: 10.1038/s41374-018-0057-0 – ident: e_1_2_10_37_1 doi: 10.15252/emmm.201809889 – ident: e_1_2_10_14_1 doi: 10.1245/s10434-006-9043-7 – ident: e_1_2_10_34_1 doi: 10.3390/ijms19020608 – ident: e_1_2_10_36_1 doi: 10.1038/modpathol.2011.148 – ident: e_1_2_10_32_1 doi: 10.1038/modpathol.2011.219 – ident: e_1_2_10_41_1 doi: 10.18632/oncotarget.10373 – volume-title: Enzinger and Weiss's Soft Tissue Tumors year: 2019 ident: e_1_2_10_7_1 contributor: fullname: Goldblum J – ident: e_1_2_10_42_1 doi: 10.1007/s13277-015-4351-9 – ident: e_1_2_10_45_1 doi: 10.1186/1747-1028-5-11 – ident: e_1_2_10_29_1 doi: 10.1093/nar/gkw937 – ident: e_1_2_10_11_1 doi: 10.1155/2011/538085 – ident: e_1_2_10_3_1 doi: 10.1007/978-1-4899-8032-8_25 – ident: e_1_2_10_20_1 doi: 10.1148/radiol.2282011860 – volume-title: Soft Tissue and Bone Tumours year: 2020 ident: e_1_2_10_6_1 contributor: fullname: WHO Classification of Tumours Editorial Board – ident: e_1_2_10_33_1 doi: 10.1111/j.0006-341X.2000.00337.x – ident: e_1_2_10_9_1 doi: 10.1002/cncr.27847 – ident: e_1_2_10_30_1 doi: 10.1038/nprot.2012.004 – ident: e_1_2_10_40_1 doi: 10.1038/bjc.2012.424 – ident: e_1_2_10_26_1 doi: 10.1093/bioinformatics/btp616 – ident: e_1_2_10_4_1 doi: 10.1038/nrc3219 – ident: e_1_2_10_44_1 doi: 10.1186/1747-1028-3-4 – ident: e_1_2_10_12_1 doi: 10.1002/(SICI)1097-0142(19960415)77:8<1450::AID-CNCR5>3.0.CO;2-G – ident: e_1_2_10_38_1 doi: 10.1038/s41598-019-56247-8 – ident: e_1_2_10_35_1 doi: 10.1186/1756-9966-33-33 – ident: e_1_2_10_15_1 doi: 10.1111/cas.15256 – ident: e_1_2_10_23_1 doi: 10.1038/s41598-017-17204-5 – ident: e_1_2_10_39_1 doi: 10.1186/s12964-018-0266-6 – ident: e_1_2_10_2_1 doi: 10.1159/000508780 – ident: e_1_2_10_16_1 doi: 10.1002/cncr.22720 – ident: e_1_2_10_43_1 doi: 10.1007/s00432-020-03438-w – ident: e_1_2_10_5_1 doi: 10.3390/uro1010002 – ident: e_1_2_10_46_1 doi: 10.1515/BC.2007.159 – volume-title: Urinary and Male Genital Tumours year: 2022 ident: e_1_2_10_18_1 contributor: fullname: WHO Classification of Tumours Editorial Board – ident: e_1_2_10_22_1 doi: 10.1038/s41467-022-30847-x – ident: e_1_2_10_17_1 doi: 10.1002/path.1848 – ident: e_1_2_10_25_1 doi: 10.1002/cjp2.16 – ident: e_1_2_10_10_1 doi: 10.1245/s10434-011-2127-z – ident: e_1_2_10_21_1 doi: 10.11613/BM.2012.031 |
SSID | ssj0036494 |
Score | 2.4712303 |
Snippet | Myxoid liposarcoma (MLS) accounts for 20%‐30% of liposarcoma and the round cell component (RCC) is believed to be a specific poor prognostic factor. However,... Myxoid liposarcoma (MLS) accounts for 20%-30% of liposarcoma and the round cell component (RCC) is believed to be a specific poor prognostic factor. However,... |
SourceID | pubmedcentral proquest crossref pubmed wiley |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 2178 |
SubjectTerms | Adult Carcinoma, Renal Cell - pathology Cell cycle cell cycle–related gene Cell density Cyclin-dependent kinases Cytology DNA damage Gene expression Genes Genetic testing Humans Immunohistochemistry Kidney Neoplasms - pathology Kinases Liposarcoma Liposarcoma, Myxoid - genetics Lymphocytes Medical prognosis Morphology Morphometry myxoid liposarcoma nuclear atypia Open source software Original Pathology Polo-like kinase 1 Prognosis Proteins Renal cell carcinoma round cell component Survival Analysis Telomerase |
Title | Prognostic value of nuclear morphometry in myxoid liposarcoma |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcas.15729 https://www.ncbi.nlm.nih.gov/pubmed/36661410 https://www.proquest.com/docview/2808449165 https://search.proquest.com/docview/2768242582 https://pubmed.ncbi.nlm.nih.gov/PMC10154898 |
Volume | 114 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-QwDLYYDogLWpZXl4eyiAOXMmnTNulxNAvaCyskQOJWpXmISrQdzTAS_HuctB2BRlz2VjVpY9lObCfOZ4ALVXJjKLWhytxuVcZ1WOYyDSNW2oiWJmbWb13c839P4s-1g8nJhrswPmlfldVV81JfNdWzz62c1Wo85ImN726nkXe0czEewQidwyFG79ZfliV5V8o24WFOWdzjCbn8HVdGLErxk23YYpkzTe7m7GeDtOZlridLfnZivRW6-QE7vftIJh2Zu7Bhmp-wddsfkO-BQ793qXPYTByOtyGtJY3DLJZzUrfI1LY2r_N3UjWkfn9rK01eqlm7QHVva7kPjzfXD9O_YV8hIVQpS_JQqZjKGFconFcyKi2jIjFU5xL9DKa4lJJqfJPiTGUp11nCy4ypyAVZ1DKm2QFsNm1jjoBYZJtNKcpN6ARtuBBGlNoYzlUsrUoDOB_YVMw6IIxiCCCQrYVnawAnAwOLfi4silggVQm6ofiP36tm1GJ3NCEb0y6xD0Y9LvgRcQCHHb9XowyCCkB8kcSqg0PI_tqCiuORsgdFCeDSC-17yovp5N4__Pr_UY5h2xWj79IhT2Dzdb40pzBa6OWZD_XPvJ5-AAUM6uo |
link.rule.ids | 230,315,729,782,786,866,887,27933,27934,53800,53802 |
linkProvider | National Library of Medicine |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB7xkCgXoA_aFGhd1EMvYZ04iZ0jWkBUZVElQOotcvwQkUiy2mUl-PcdO8kKhLhwizJWnPjLeGbs8TcAP1XJjaHUhipzq1UZ12GZyzSMWGkjWpqYWb90ccUv_4mTU0eTkw1nYXzSviqro-auPmqqW59bOa3VaMgTG_2djCPvaOditArrqLCUDlF6NwOzLMm7YrYJD3PK4p5RyGXwuEJiUYoe5SZssMwZJ3d29qlJeuFnvkyXfOrGejt0tv3WL9iBrd7zJMed_D2smOYDbEz6vfWP4IjzXdYdiomjADektaRxdMdyRuoW8Whrcz97JFVD6seHttLkrpq2c9SUtpaf4Obs9Hp8HvbFFUKVsiQPlYqpjHFyQ5WUUWkZFYmhOpfoojDFpZRU450UlZylXGcJLzOmIhefUcuYZruw1rSN-QLE4njblCLkQido_oUwotTGcK5iaVUawOEwvsW049AohtgD8Sg8HgHsDyNf9Go0L2KBb5WgB4vP-LEUowK4XQ3ZmHaBbTBgcnGTiAP43AG17GVAOADxDMJlA0eu_VyCiHmS7QGhAH55tF9_82J8fOUvvr69l-_w7vx6clFc_L78swebrqZ9l1W5D2v3s4U5gNW5Xnzzv_l_V9P_sg |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwEB0VkFZc2tIPSEupqThwCevESez0hhZWrQoICSr1Fjn-EJFIstplpfLvO3aSFQj1ArcotuLEL2O_scdvAA5UyY2h1IYqc6tVGddhmcs0jFhpI1qamFm_dHHFL_6Ik1Mnk_N9OAvjg_ZVWR01t_VRU9342MpZrcZDnNj48nwSeaKdi_FM2_EabKDR0njw1LtRmGVJ3iW0TXiYUxb3qkIuisclE4tSZJWbMGKZm6Dc-dmH09ITrvk0ZPIhlfVz0fTNS77iLbzuGSg57upswSvTvIPReb_H_h6cgL6LvsNi4qTADWktaZzssZyTukVc2trcze9J1ZD6_m9baXJbzdoFWkxbyw_we3p6PfkR9kkWQpWyJA-ViqmMcZBD05RRaRkViaE6l0hVmOJSSqrxTorGzlKus4SXGVOR89OoZUyzj7DetI3ZAWKxz21KEXqhE6QBQhhRamM4V7G0Kg3g29DHxazT0igGHwQxKTwmAewOvV_05rQoYoFvlSCTxWfsr4rRENzuhmxMu8Q66Dg5_0nEAWx3YK1aGVAOQDyCcVXBiWw_LkHUvNj2gFIAhx7x_795MTm-8hefnt_KVxhdnkyLs58Xvz7Dpktt3wVX7sL63XxpvsDaQi_3_J_-D3wVAkE |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+value+of+nuclear+morphometry+in+myxoid+liposarcoma&rft.jtitle=Cancer+science&rft.au=Kawaguchi%2C+Kengo&rft.au=Kohashi%2C+Kenichi&rft.au=Iwasaki%2C+Takeshi&rft.au=Yamamoto%2C+Takeo&rft.date=2023-05-01&rft.issn=1347-9032&rft.eissn=1349-7006&rft.volume=114&rft.issue=5&rft.spage=2178&rft.epage=2188&rft_id=info:doi/10.1111%2Fcas.15729&rft.externalDBID=10.1111%252Fcas.15729&rft.externalDocID=CAS15729 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-9032&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-9032&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-9032&client=summon |